Guilin Sanjin released its performance for the first three quarters, with a net profit attributable to the parent company of 385 million yuan, a year-on-year increase of 0.35%Zhitong·Oct 29, 2025 at 08:50 AM002275+0.15%
Guilin Sanjin plans to distribute 118 million yuan in cash in the first three quarters of 2025Zhitong·Oct 29, 2025 at 03:24 AM002275+0.15%
Guilin Sanjin provides an additional guarantee of 20 million yuan for its subsidiary Baochuan BiotechnologyZhitong·Sep 4, 2025 at 03:39 AM002275+0.15%
A-share pharmaceutical stocks continue to adjust, CheezhengTTM approaches the limit down, and multiple stocks such as Xintian Pharmaceutical, Hanyu Pharmaceutical, Guilin Sanjin, Foci Pharmaceutical, YIBAI PHARMACEUTICAL, Zhendong Pharmacy, and Cosunter have fallen over 5%Wallstreetcn·Aug 6, 2025 at 01:41 AM300158+1.44%002287+0.38%
The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin falling over 6%Zhitong·Aug 5, 2025 at 08:52 PM002275+0.15%300199+4.46%
Global Dividend Stocks To Consider In June 2025Simplywall·Jun 4, 2025 at 04:16 AM002275+0.15%ORN+5.40%
Guilin Sanjin: BC006 monoclonal antibody injection new indication approved for clinical trialsZhitong·May 5, 2025 at 02:59 AM002275+0.15%
